[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-354096-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-354096-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","early-adoption-of-image-guided-histotripsy-therapy-in-interventional-oncology-challenges-and-opportunities-in-the-united-kingdom","Early adoption of image-guided histotripsy therapy in interventional oncology - challenges and opportunities in the United Kingdom","","Histotripsy represents a paradigm shift in interventional oncology as the first non-invasive, non-ionizing and nonthermal ultrasound-based ablation technology for cancer therapy. Compared with thermal ablation, it offers tissue-selective treatment near critical structures, lower collateral injury risk, and predictable margins unaffected by the heat-sink phenomenon. Early feasibility and pivotal trials have been promising in liver cancer, with expanding translational studies in renal and pancreatic malignancies.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/early-adoption-of-image-guided-histotripsy-therapy-in-interventional-oncology-challenges-and-opportunities-in-the-united-kingdom/354096/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/early-adoption-of-image-guided-histotripsy-therapy-in-interventional-oncology-challenges-and-opportunities-in-the-united-kingdom/354096.png","ImageObject",300,407,{"name":42,"@type":43},"Melati","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-31","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is histotripsy and how does it differ from thermal ablation in interventional oncology?","Question",{"text":63,"@type":64},"Histotripsy is an ultrasound-based, non-invasive, non-ionizing, non-thermal ablation approach that uses acoustic pulses to generate localized bubble clouds. It provides tissue-selective ablation near critical structures and avoids heat-sink-related effects seen with thermal techniques.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which cancer areas have shown promising early evidence for histotripsy?",{"text":68,"@type":64},"Early phase feasibility and pivotal trial results have been promising for liver cancers. Emerging translational trials are also reported in renal and pancreatic cancers.",{"name":70,"@type":61,"acceptedAnswer":71},"What are the main clinical and system-level challenges for adopting histotripsy in the NHS?",{"text":72,"@type":64},"Key challenges include the learning curve for operators and teams, navigating regulatory processes, and synthesizing health economic evidence needed to support broader NHS commissioning and integration.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},354096,1790737261,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},962085570644,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","Early adoption of image-guided histotripsy therapy in interventional oncology: challenges and opportunities in the United Kingdom  \nHelen Hoi Lam Ng, MBChB\\#,1,2, , Vinson Wai-Shun Chan, MBChB\\#,1,2, , Lewis Howell, MSci3,4, , Taha Shiwani, MBBs, iBSc1, , Jim Zhong, PhD, MBChB, BSc(Hons)1,2, ,  \nJacqueline Brandon, BSc (Hons), MSc1, Adel Samson, PhD, MBChB, BSc2, James Chandler, PhD, MEng4, , James McLaughlan, PhD, MPhys2,4, , Tze Min Wah, PhD, MSc, MBChB*,1,2,   \n1 Department of Diagnostic and Interventional Radiology, St. James’s University Hospital, Leeds Teaching Hospitals NHS Trust, Leeds LS9 7TF,  \nUnited Kingdom  \n2 Leeds Institute of Medical Research, Faculty of Medicine and Health, University of Leeds, Leeds LS2 9JT, United Kingdom 3School of Computer Science, Faculty of Engineering and Physical Sciences, University of Leeds, Leeds LS2 9JT, United Kingdom  \n4School of Electronic and Electrical Engineering, Faculty of Engineering and Physical Sciences, University of Leeds, Leeds LS2 9JT, United Kingdom  \n*Corresponding author: Tze Min Wah, PhD, MSc, MBChB, Department of Diagnostic and Interventional Radiology, St. James’s University Hospital, Leeds Teaching Hospitals NHS Trust, Beckett St, Leeds LS9 7TF, United Kingdom ([tze.wah@nhs. net](tze.wah@nhs. net)) .  \n\\# Helen Hoi Lam Ng and Vinson Wai-Shun Chan contributed equally to this work.  \nAbstract  \nHistotripsy represents a paradigm shift in interventional oncology (IO) as the first non-invasive, non-ionizing and nonthermal ultrasound-based ablation technology available for cancer therapy. Compared with thermal ablation techniques, the advantages of histotripsy include tissue-selective ablation near critical structures, reduced collateral injury risk, and treatment which is unaffected by the heat sink phenomenon, ensuring predictable treatment margins. Ultrasound technology can be constrained by tissue attenuation depending on the depth of the target; however, the early phase feasibility and pivotal trial results have been promising for its application in liver cancers, with emerging translational trials in renal and pancreatic cancer. In the United Kingdom, 2 well-established IO sites have participated in the pivotal \\#HOPE4LIVER Trial that led to approval by the US Food and Drug Administration in liver tumours therapy in 2023 and obtained Medicines and Healthcare products Regulatory Agency Unmet Clinical Need Authorisation for treatment of liver tumoursin United Kingdom (April 2025) via the Innovative Devises Access Pathway. The global-first feasibility in renal cancer (CAIN trial) was also led by the United Kingdom and completed in April 2024. This review provides an overview of histotripsy and highlights the clinical challenges in early National Health Service (NHS) adoption such as the learning curve for operators and teams, regulatory processes, and synthesis of health economic evidence required for wider NHS commissioning. The review will also discuss the future directions of histotripsy, including combination immunomodulatory therapies, highlighting the need for continual national collaboration for successful integration in the NHS. Successfully integrating this technology into the NHS hinges on a unified national effort to navigate the clinical, regulatory and economic hurdles, ensuring its benefits reach patients nationwide.  \nKey words Histotripsy, Interventional Oncology, Interventional Radiology, Medical Technology, United Kingdom, Ultrasonic Therapy  \nIntroduction  \nMedical interventions are undergoing a notable shift towards less invasive procedures, with numerous diseases amenable to minimally invasive approaches, facilitated by improved image guidance. Percutaneous needle-based thermal and non-thermal ablation techniques, including radiofrequency (RFA), microwave (MWA), cryoablation and irreversible electroporation (IRE), are  \nwidely described and have demonstrated success across diverse applications.1  \nImage-guided histotripsy ultrasound-based the","cbCaigHs8EGT1SbE","https://ap.wps.com/l/cbCaigHs8EGT1SbE","pdf",1357382,14,"English","# Abstract\n# Introduction\n## Shift toward minimally invasive, image-guided interventions\n## Histotripsy as non-invasive, non-ionizing, non-thermal ablation\n## Mechanisms: acoustic cavitation vs boiling","[{\"question\":\"What is histotripsy and how does it differ from thermal ablation in interventional oncology?\",\"answer\":\"Histotripsy is an ultrasound-based, non-invasive, non-ionizing, non-thermal ablation approach that uses acoustic pulses to generate localized bubble clouds. It provides tissue-selective ablation near critical structures and avoids heat-sink-related effects seen with thermal techniques.\"},{\"question\":\"Which cancer areas have shown promising early evidence for histotripsy?\",\"answer\":\"Early phase feasibility and pivotal trial results have been promising for liver cancers. Emerging translational trials are also reported in renal and pancreatic cancers.\"},{\"question\":\"What are the main clinical and system-level challenges for adopting histotripsy in the NHS?\",\"answer\":\"Key challenges include the learning curve for operators and teams, navigating regulatory processes, and synthesizing health economic evidence needed to support broader NHS commissioning and integration.\"}]","Early adoption of image-guided histotripsy therapy in interventional oncology - challenges and opportunities in the United Kingdom | PDF",1790108910,35,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2a30f3f2a6184bcc043df1ffd695447e.webp",983,1291,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/718377965c9633735aea71c2e0169f90.webp",982,1290,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/178982b86dd12fb7cd1e17e81b27de0d.webp",981,1289,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f76ab637614cf7bdd73c51850e21f13a.webp",980,1287]